Published in Nucleic Acids Res on December 19, 2006
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov (2012) 2.65
Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res (2008) 1.98
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature (2014) 1.87
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther (2014) 1.21
An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther (2008) 1.15
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids (2013) 1.10
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br J Pharmacol (2009) 1.01
An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA. J Am Chem Soc (2010) 0.99
Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res (2015) 0.99
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides. Nucleic Acids Res (2014) 0.94
Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry (2007) 0.93
Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release (2015) 0.92
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther (2013) 0.91
Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther (2014) 0.88
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res (2015) 0.88
Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother (2011) 0.87
Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol Ther Nucleic Acids (2012) 0.86
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids (2012) 0.86
RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today (2015) 0.84
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res (2015) 0.84
Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther (2014) 0.83
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. Acta Naturae (2013) 0.83
Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors. J Nucleic Acids (2012) 0.83
Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain. Front Genet (2016) 0.82
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun (2015) 0.81
Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function. Nucleic Acids Res (2016) 0.81
MicroRNA Therapeutics: the Next Magic Bullet? Mini Rev Med Chem (2015) 0.80
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res (2014) 0.80
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet (2015) 0.80
Small molecules targeting microRNA for cancer therapy: Promises and obstacles. J Control Release (2015) 0.80
Identification of metabolically stable 5'-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Res (2015) 0.79
Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA. Nucleic Acids Res (2010) 0.78
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis? Mol Ther (2015) 0.78
MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. Drug Dev Res (2015) 0.78
Exploring Internal Ribosome Entry Sites as Therapeutic Targets. Front Oncol (2015) 0.78
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res (2014) 0.78
From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacol Res (2013) 0.78
Towards Fluorescence In Vivo Hybridization (FIVH) Detection of H. pylori in Gastric Mucosa Using Advanced LNA Probes. PLoS One (2015) 0.78
The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol (2017) 0.77
Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Mol Ther (2017) 0.77
A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver. Mol Ther Nucleic Acids (2014) 0.77
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. Neuron (2016) 0.76
Development of Antisense Drugs for Dyslipidemia. J Atheroscler Thromb (2016) 0.76
Modulating Anti-MicroRNA-21 Activity and Specificity Using Oligonucleotide Derivatives and Length Optimization. ISRN Pharm (2012) 0.75
Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides. J Neuromuscul Dis (2016) 0.75
Targeting LDL Cholesterol With LNA. Mol Ther Nucleic Acids (2012) 0.75
Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity. Artif DNA PNA XNA (2016) 0.75
HDL and microRNA therapeutics in cardiovascular disease. Pharmacol Ther (2016) 0.75
Fluorescence In Vivo Hybridization (FIVH) for Detection of Helicobacter pylori Infection in a C57BL/6 Mouse Model. PLoS One (2016) 0.75
A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides. RNA Biol (2016) 0.75
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Sci Rep (2016) 0.75
Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med (2017) 0.75
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol (2017) 0.75
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. Int J Mol Sci (2017) 0.75
LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. Mol Ther Nucleic Acids (2017) 0.75
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci (2017) 0.75
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (2004) 9.52
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res (1988) 4.49
Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 3.70
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem (1991) 2.65
A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J Biol Chem (1997) 2.13
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation (2006) 2.08
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res (2005) 1.96
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes (2002) 1.91
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem (1999) 1.76
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther (2001) 1.73
Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry (2000) 1.72
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem (2004) 1.68
A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR. EMBO J (2000) 1.68
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA. Nat Struct Biol (1999) 1.65
Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem (2001) 1.60
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos (2003) 1.57
Double-stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 mediates apoptosis. J Biol Chem (2006) 1.53
Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev (2000) 1.50
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 1.43
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs (2001) 1.29
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1994) 1.25
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J Biol Chem (2004) 1.22
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci (2004) 1.20
Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther (2001) 1.11
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res (2003) 1.10
Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem (1996) 1.06
Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol (2002) 1.04
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther (2002) 1.02
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem (2005) 0.97
Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res (2004) 0.95
A DNA damage signal is required for p53 to activate gadd45. Cancer Res (2000) 0.92
Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol (2004) 0.91
A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides (2004) 0.89
Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS). Bioorg Med Chem Lett (2006) 0.86
Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism (2005) 0.84
Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression. Mol Pharmacol (2004) 0.82
Kilo-scale synthesis process for 2'-O-(2-methoxyethyl)-pyrimidine derivatives. Nucleosides Nucleotides Nucleic Acids (2005) 0.80
Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides. Oligonucleotides (2006) 0.79
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell (2010) 8.66
MicroRNA-143 regulates adipocyte differentiation. J Biol Chem (2004) 6.78
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci (2011) 6.01
Regulating gene expression through RNA nuclear retention. Cell (2005) 5.58
The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res (2012) 5.04
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature (2011) 4.04
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest (2006) 3.75
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 3.25
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 3.24
Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol (2008) 3.02
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A (2013) 2.95
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci (2012) 2.93
Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med (2013) 2.89
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep (2012) 2.45
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab (2009) 2.35
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 2.29
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest (2006) 2.13
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res (2007) 1.99
Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res (2008) 1.98
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest (2004) 1.93
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes (2002) 1.91
SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A (2009) 1.89
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res (2011) 1.84
Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest (2004) 1.83
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther (2011) 1.82
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes (2004) 1.65
Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem (2009) 1.61
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem (2004) 1.57
Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 1.54
Antisense therapy for cancer. Nat Rev Cancer (2005) 1.54
Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry (2010) 1.50
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther (2006) 1.46
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest (2013) 1.44
Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res (2012) 1.42
Therapeutic potential for microRNAs. Adv Drug Deliv Rev (2007) 1.41
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem (2004) 1.41
RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A (2012) 1.40
Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'O-ethyl nucleic acid analogues. J Org Chem (2010) 1.36
Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest (2005) 1.35
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res (2010) 1.35
Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A (2006) 1.35
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab (2009) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology (2006) 1.29
Antisense reduction of tau in adult mice protects against seizures. J Neurosci (2013) 1.29
Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol (2012) 1.25
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res (2005) 1.24
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology (2008) 1.24
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res (2013) 1.23
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat Chem Biol (2012) 1.22
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood (2011) 1.22
Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res (2007) 1.18
Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol (2003) 1.18
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol Pharmacol (2006) 1.18
Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid (2012) 1.16
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol (2003) 1.16
Bcl-2 sustains increased mucous and epithelial cell numbers in metaplastic airway epithelium. Am J Respir Crit Care Med (2004) 1.14
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med (2012) 1.14
Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation. Mol Endocrinol (2002) 1.09
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes (2002) 1.07
PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene (2002) 1.05
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood (2014) 1.05
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res (2004) 1.04
Antibacterial aminoglycosides with a modified mode of binding to the ribosomal-RNA decoding site. Angew Chem Int Ed Engl (2004) 1.04
Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol Chem (2011) 1.03
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res (2002) 1.02
Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J Virol (2003) 1.01